Literature DB >> 32905553

Towards COVID-19 Prophylaxis: An AIDS Preclinical Research Perspective.

Michele Di Mascio1.   

Abstract

The success of an antiviral drug depends on its potency to neutralize the virus in vitro and its ability after administration in vivo to reach the anatomic compartments that fuel viral dissemination in the body. For instance, remdesivir, a potent SARS-CoV-2 antiviral drug based on studies in vitro, if administered orally would be poorly effective because low drug levels would reach the lungs due to its high first pass destruction in the liver. This is the reason remdesivir can only be administered intravenously, a requirement that clearly limits its use as a prophylactic agent for COVID-19, although novel formulations for its easier administration are under development. Whether an antiviral prophylaxis could further control or even stop the COVID-19 epidemic in synergy with other non-pharmacological based mitigation strategies is today unknown. Since the mid-1960s, pharmacologists have investigated the use of lipid-based nanoparticles for efficient delivery of antivirals to tissues, for example by transforming the route of administration from intravenous to oral, subcutaneous or aerosol administrations. These novel encapsulation strategies have also the potential to maintain high levels of the antiviral drugs in tissues, with reduced dose frequency compared to the non-encapsulated drug. Several lipid-based nanoparticles are today approved by the US Food and Drug Administration or being tested in clinical studies with favorable toxicity profiles. Nonhuman primate models of coronavirus infection offer unique platforms to accelerate the search for SARS-CoV-2 antiviral prophylaxis. Paradigms, to corroborate this claim, are borrowed from nonhuman primate research studies, some of which had a profound impact on global public health in the specific setting of the AIDS pandemic. Sharing information from nonhuman primate research programs, invoking principles of scientific transparency and bioethics similar to those universally agreed for human studies, would also likely significantly help our collective fight (as the human species) against this public health emergency.

Entities:  

Year:  2020        PMID: 32905553      PMCID: PMC7472709     

Source DB:  PubMed          Journal:  Cancer Stud Ther


  50 in total

1.  To Treat Primates More Humanely: Transparency.

Authors:  Monique Brouillette
Journal:  Sci Am       Date:  2017-01-17       Impact factor: 2.142

2.  Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection.

Authors:  J Gerardo García-Lerma; Mian-er Cong; James Mitchell; Ae S Youngpairoj; Qi Zheng; Silvina Masciotra; Amy Martin; Zsuzsanna Kuklenyik; Angela Holder; Jonathan Lipscomb; Chou-Pong Pau; John R Barr; Debra L Hanson; Ron Otten; Lynn Paxton; Thomas M Folks; Walid Heneine
Journal:  Sci Transl Med       Date:  2010-01-13       Impact factor: 17.956

3.  Deposition and disposition of [11C]zanamivir following administration as an intranasal spray. Evaluation with positron emission tomography.

Authors:  M Bergstrom; L M Cass; S Valind; G Westerberg; E L Lundberg; S Gray; A Bye; B Langstrom
Journal:  Clin Pharmacokinet       Date:  1999       Impact factor: 6.447

4.  Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection.

Authors:  Lisa A McConnachie; Loren M Kinman; Josefin Koehn; John C Kraft; Sarah Lane; Wonsok Lee; Ann C Collier; Rodney J Y Ho
Journal:  J Pharm Sci       Date:  2018-03-13       Impact factor: 3.534

5.  Short-lived infected cells support virus replication in sooty mangabeys naturally infected with simian immunodeficiency virus: implications for AIDS pathogenesis.

Authors:  Shari N Gordon; Richard M Dunham; Jessica C Engram; Jacob Estes; Zichun Wang; Nichole R Klatt; Mirko Paiardini; Ivona V Pandrea; Cristian Apetrei; Donald L Sodora; Ha Youn Lee; Ashley T Haase; Michael D Miller; Amitinder Kaur; Silvija I Staprans; Alan S Perelson; Mark B Feinberg; Guido Silvestri
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

6.  Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.

Authors:  Michael S Saag; Constance A Benson; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Michael J Mugavero; Paul E Sax; Davey M Smith; Melanie A Thompson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding
Journal:  JAMA       Date:  2018-07-24       Impact factor: 56.272

7.  Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.

Authors:  Emmie de Wit; Friederike Feldmann; Jacqueline Cronin; Robert Jordan; Atsushi Okumura; Tina Thomas; Dana Scott; Tomas Cihlar; Heinz Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-13       Impact factor: 11.205

8.  Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study.

Authors:  Dominic Wichmann; Jan-Peter Sperhake; Marc Lütgehetmann; Stefan Steurer; Carolin Edler; Axel Heinemann; Fabian Heinrich; Herbert Mushumba; Inga Kniep; Ann Sophie Schröder; Christoph Burdelski; Geraldine de Heer; Axel Nierhaus; Daniel Frings; Susanne Pfefferle; Heinrich Becker; Hanns Bredereke-Wiedling; Andreas de Weerth; Hans-Richard Paschen; Sara Sheikhzadeh-Eggers; Axel Stang; Stefan Schmiedel; Carsten Bokemeyer; Marylyn M Addo; Martin Aepfelbacher; Klaus Püschel; Stefan Kluge
Journal:  Ann Intern Med       Date:  2020-05-06       Impact factor: 25.391

9.  A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.

Authors:  Bin Cao; Yeming Wang; Danning Wen; Wen Liu; Jingli Wang; Guohui Fan; Lianguo Ruan; Bin Song; Yanping Cai; Ming Wei; Xingwang Li; Jiaan Xia; Nanshan Chen; Jie Xiang; Ting Yu; Tao Bai; Xuelei Xie; Li Zhang; Caihong Li; Ye Yuan; Hua Chen; Huadong Li; Hanping Huang; Shengjing Tu; Fengyun Gong; Ying Liu; Yuan Wei; Chongya Dong; Fei Zhou; Xiaoying Gu; Jiuyang Xu; Zhibo Liu; Yi Zhang; Hui Li; Lianhan Shang; Ke Wang; Kunxia Li; Xia Zhou; Xuan Dong; Zhaohui Qu; Sixia Lu; Xujuan Hu; Shunan Ruan; Shanshan Luo; Jing Wu; Lu Peng; Fang Cheng; Lihong Pan; Jun Zou; Chunmin Jia; Juan Wang; Xia Liu; Shuzhen Wang; Xudong Wu; Qin Ge; Jing He; Haiyan Zhan; Fang Qiu; Li Guo; Chaolin Huang; Thomas Jaki; Frederick G Hayden; Peter W Horby; Dingyu Zhang; Chen Wang
Journal:  N Engl J Med       Date:  2020-03-18       Impact factor: 91.245

Review 10.  The journey of remdesivir: from Ebola to COVID-19.

Authors:  Joe Pardo; Ashutosh M Shukla; Gajapathiraju Chamarthi; Asmita Gupte
Journal:  Drugs Context       Date:  2020-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.